Skip to content

Return on equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
38.8%+7.3pp
Amgen logo
AmgenAMGN
101.3%-4.4pp
Tango Therapeutics logo
Tango TherapeuticsTNGX
-38.4%-10.5pp
Arcus Biosciences logo
Arcus BiosciencesRCUS
-70%+8.4pp
Erasca, Inc. logo
Erasca, Inc.ERAS
-69.9%+77.1pp
Immunome logo
ImmunomeIMNM
-50.1%-10.8pp

Other financials

Income statement

See full
Revenue$6.6M
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%
EPS (diluted)-$1.11-35.4%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total equity$937.3M-8.5%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%
Free cash flow-$76.1M-23.5%

Valuation

See full
Market cap$3.36B+104%
Enterprise value$3.23B+110%
P/S14.5×+9.9×

Profitability

See full
Operating margin-4,671.1%-5,434pp
Net margin-3,921.1%-4,562pp
FCF margin-3,592%-4,290pp

Returns & leverage

See full
Debt / equity0.0×
Current ratio10.7×-3.2×

Where this comes from

Calculated from IDEAYA Biosciences, Inc.’s reported figures.

Based on trailing twelve months.

The official record: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about IDEAYA Biosciences, Inc.'s return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is IDEAYA Biosciences, Inc.'s return on equity?
IDEAYA Biosciences, Inc. (IDYA) reported return on equity of -14.3% in Q1 2026.
How has IDEAYA Biosciences, Inc.'s return on equity changed year-over-year?
IDEAYA Biosciences, Inc.'s return on equity increased by 54.4% year-over-year, from -31.3% to -14.3%.
What is the long-term trend for IDEAYA Biosciences, Inc.'s return on equity?
Over 5 years (2020 to 2025), IDEAYA Biosciences, Inc.'s return on equity has grown at a -13.9% compound annual growth rate (CAGR), from -23.1% to -10.9%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.